Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Regeneron Pharmaceuticals is the lead sponsor of 105 current clinical trials in our USA, UK, Ireland, China, India and EU (CTIS) registers. 59 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Cemiplimab, Linvoseltamab and Fianlimab. The most-studied condition is Melanoma.

Company profiles on this site (news, sites, medicines, approvals): Regeneron Ireland (IE) →Regeneron Pharmaceuticals (US) →

ClinicalTrials.gov trials by status

Recruiting5964%
Active, closed3235%
By invitation11%

Trials by phase

Phase 32932%
Phase 22325%
Phase 1/21820%
Phase 1910%
Observational910%
Phase 422%
Phase 2/322%

Clinical trials sponsored by Regeneron Pharmaceuticals

92 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma NCT06091865 · Diffuse Large B-cell Lymphoma (DLBCL) Drugs: Cyclophosphamide, Doxorubicin, Odronextamab	Phase 3	Recruiting	2023-12	Ireland, UK, USA
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) NCT03936335 · Adverse Pregnancy Outcomes, Atopic Dermatitis Drug: Dupilumab	Observational	Recruiting	2019-09	USA
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma NCT06140524 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Drug: Linvoseltamab	Phase 2	Recruiting	2024-09	Ireland, USA
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT07222761 · Relapsed and/or Refractory Multiple Myeloma (RRMM) Drugs: Bortezomib, Carfilzomib, Daratumumab	Phase 3	Recruiting	2026-01	UK, USA
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works NCT05744921 · Paroxysmal Nocturnal Hemoglobinuria Drugs: Cemdisiran, Pozelimab	Phase 3	Recruiting	2023-03	UK, India, China
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer NCT05125016 · Metastatic Castration-resistant Prostate Cancer Drugs: REGN4336, REGN5678	Phase 1/2	Recruiting	2021-11	USA
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma NCT03761108 · Multiple Myeloma Drug: Linvoseltamab	Phase 1/2	Recruiting	2019-01	UK, USA
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma NCT05730036 · ClinicalTrials.gov ↗ · Relapsed Refractory Multiple Myeloma (RRMM) Drugs: Dexamethasone, Elotuzumab, Linvoseltamab	Phase 3	Recruiting	2023-09	UK, USA
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) NCT06292780 · ClinicalTrials.gov ↗ · Relapsed/Refractory Systemic Light Chain Amyloidosis Drug: Linvoseltamab	Phase 1/2	Recruiting	2024-08	UK, USA
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma NCT06149286 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) Drugs: Lenalidomide, Odronextamab, Rituximab	Phase 3	Recruiting	2023-12	UK, USA
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas NCT05685173 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkins Lymphoma (B-NHL) Drug: Odronextamab	Phase 1	Recruiting	2023-04	UK, USA
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD NCT07527910 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Drug: Tirzepatide	Phase 2	Recruiting	2026-05	USA
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma NCT06091254 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL) Drugs: Bendamustine, Cyclophosphamide, Doxorubicin	Phase 3	Recruiting	2023-12	UK, USA
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) NCT06836609 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis	Phase 1/2	Recruiting	2025-04	UK, USA
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition NCT05519475 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated SteatoHepatitis (MASH)	Phase 2	Recruiting	2023-02	USA
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) NCT07318597 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension (PAH)	Phase 2	Recruiting	2026-05	UK, USA
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) NCT07393282 · ClinicalTrials.gov ↗ · High Risk Smoldering Multiple Myeloma (HR-SMM) Drugs: Daratumumab, Linvoseltamab	Phase 3	Recruiting	2026-05	UK, USA
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers NCT07493304 · ClinicalTrials.gov ↗ · Venous Thromboembolism (VTE) Drugs: Apixaban, Cenvacibart	Phase 3	Recruiting	2026-08	USA
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor NCT07187401 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia	Phase 1/2	Recruiting	2026-02	UK
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B NCT06379789 · ClinicalTrials.gov ↗ · Hemophilia B	Phase 1/2	Recruiting	2024-09	UK, USA
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body NCT06413680 · ClinicalTrials.gov ↗ · Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors Drugs: Cemiplimab, REGN10597	Phase 1/2	Recruiting	2024-09	USA
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation NCT07626411 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF) Drugs: Apixaban, Cenvacibart	Phase 3	Recruiting	2026-08	USA
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy NCT06541704 · ClinicalTrials.gov ↗ · Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) Drugs: Cemdisiran, Pozelimab	Phase 3	Recruiting	2024-10	UK, USA
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma NCT06669247 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma Drug: Linvoseltamab	Phase 1/2	Recruiting	2024-12	UK
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers NCT03564340 · ClinicalTrials.gov ↗ · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer Drugs: Cemiplimab, Sarilumab, Tocilizumab	Phase 1/2	Recruiting	2018-05	UK, USA
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) NCT05648214 · ClinicalTrials.gov ↗ · Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Phase 1/2	Recruiting	2022-12	USA
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations NCT05788536 · ClinicalTrials.gov ↗ · Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)	Phase 1/2	Recruiting	2023-06	UK, USA
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea NCT07235917 · ClinicalTrials.gov ↗ · Functional Hypothalamic Amenorrhea (FHA) Drug: Mibavademab	Phase 2	Recruiting	2026-03	USA
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis NCT07112378 · ClinicalTrials.gov ↗ · Eosinophilic Esophagitis (EoE) Drug: Dupilumab	Phase 3	Recruiting	2025-11	USA
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors NCT03972657 · ClinicalTrials.gov ↗ · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) Drugs: Cemiplimab, REGN5678	Phase 1/2	Recruiting	2019-08	USA
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease NCT07271186 · ClinicalTrials.gov ↗ · Diabetic Kidney Disease (DKD)	Phase 2	Recruiting	2026-01	USA
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation NCT07175428 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF) Drugs: Apixaban, Cenvacibart, REGN9933	Phase 2	Recruiting	2025-10	USA
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07154290 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer Drugs: Marlotamig, Sarilumab, Ubamatamab	Phase 2	Recruiting	2026-03	USA
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants NCT07213778 · ClinicalTrials.gov ↗ · Symptomatic Venous Thromboembolism (VTE) Drug: Cenvacibart	Phase 3	Recruiting	2025-11	USA
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread NCT07543055 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 1	Recruiting	2026-09	USA
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy NCT07675811 · ClinicalTrials.gov ↗ · Allergic Conjunctivitis	Phase 3	Recruiting	2026-07	USA
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes NCT07685808 · ClinicalTrials.gov ↗ · Overweight or Obesity Drug: Olatorepatide	Phase 2	Recruiting	2026-07	USA
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells NCT06798298 · ClinicalTrials.gov ↗ · Long Term Safety Following GM T Cell Therapy	Observational	Recruiting	2025-11	USA
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments NCT05137054 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Bortezomib, Carfilzomib, Cemiplimab	Phase 1	Recruiting	2022-08	USA
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma NCT07594106 · ClinicalTrials.gov ↗ · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) Drugs: Cemiplimab, REGN4336	Phase 1/2	Recruiting	2026-07	USA
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis NCT06975787 · ClinicalTrials.gov ↗ · Lupus Nephritis (LN) Drugs: Odronextamab, Vonsetamig	Phase 1	Recruiting	2025-12	USA
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) NCT06246916 · ClinicalTrials.gov ↗ · Melanoma Drugs: Cemiplimab, Fianlimab, Nivolumab	Phase 3	Recruiting	2024-09	USA
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis NCT07527923 · ClinicalTrials.gov ↗ · Healthy Volunteer, Atopic Dermatitis	Phase 1	Recruiting	2026-05	USA
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) NCT07609940 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma (RRMM) Drugs: Linvoseltamab, Tocilizumab	Phase 4	Recruiting	2026-07	USA
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable NCT07430956 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF) Drugs: Cenvacibart, REGN9933	Phase 3	Recruiting	2026-04	USA
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults NCT07015905 · ClinicalTrials.gov ↗ · Venous Thromboembolism (VTE) Drugs: Apixaban, Cenvacibart, Enoxaparin	Phase 3	Recruiting	2025-06	USA
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer NCT06787612 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Drugs: Bevacizumab, Cemiplimab, Fianlimab	Phase 2	Recruiting	2025-05	USA
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity NCT07594093 · ClinicalTrials.gov ↗ · Overweight or Obesity	Phase 1	Recruiting	2026-06	USA
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis NCT07410117 · ClinicalTrials.gov ↗ · Cancer-Associated Thrombosis (CAT)	Phase 3	Recruiting	2026-03	USA
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia NCT07477704 · ClinicalTrials.gov ↗ · Hypercholesterolemia Drug: Alirocumab	Phase 2	Recruiting	2026-06	USA
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy NCT07220785 · ClinicalTrials.gov ↗ · Generalized Lipodystrophy Drug: Mibavademab	Phase 3	Recruiting	2026-03	USA
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment NCT05828511 · ClinicalTrials.gov ↗ · Multiple Myeloma Drug: Linvoseltamab	Phase 1/2	Recruiting	2023-12	USA
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT06769698 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC) Drug: Cemiplimab	Phase 2	Recruiting	2026-04	USA
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease NCT07318610 · ClinicalTrials.gov ↗ · Peripheral Artery Disease (PAD) Drugs: Cenvacibart, REGN9933, Rivaroxaban	Phase 3	Recruiting	2026-07	USA
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma NCT06585410 · ClinicalTrials.gov ↗ · Cutaneous Squamous Cell Carcinoma (CSCC) Drug: Cemiplimab	Phase 3	Recruiting	2025-01	USA
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab NCT04590326 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Drugs: Cemiplimab, Sarilumab, Ubamatamab	Phase 1/2	Recruiting	2020-12	USA
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants NCT07230834 · ClinicalTrials.gov ↗ · Geographic Atrophy (GA) Drug: Pozelimab	Phase 1	Recruiting	2026-01	USA
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers NCT06469281 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer Drugs: Bevacizumab, Cemiplimab	Phase 1	Recruiting	2024-08	USA
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant NCT05106387 · ClinicalTrials.gov ↗ · Chronic Kidney Disease (CKD)	Observational	Recruiting	2023-10	USA
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment NCT06848088 · Melanoma Drugs: Cemiplimab, Fianlimab	Phase 2	By invitation	2025-04	Ireland, USA
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body NCT06421636 · Non-Transfusion Dependent Beta-Thalassemia (NTDT)	Phase 2	Active, closed	2024-09	UK, USA, India
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment NCT05133531 · Paroxysmal Nocturnal Hemoglobinuria Drugs: Cemdisiran, Eculizumab, Pozelimab	Phase 3	Active, closed	2022-08	UK, USA, India, China
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma NCT05352672 · Melanoma Drugs: Cemiplimab, Fianlimab, Pembrolizumab	Phase 3	Active, closed	2022-07	Ireland, UK, USA
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery NCT05608291 · Melanoma Drugs: Cemiplimab, Fianlimab, Pembrolizumab	Phase 3	Active, closed	2023-01	Ireland, UK, USA
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma NCT03969004 · ClinicalTrials.gov ↗ · Cutaneous Squamous Cell Carcinoma Drug: Cemiplimab	Phase 3	Active, closed	2019-06	Ireland, UK, USA
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) NCT03428646 · Dermatitis, Atopic Drug: Dupilumab	Observational	Active, closed	2018-04	USA
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis NCT05070858 · ClinicalTrials.gov ↗ · Generalized Myasthenia Gravis Drugs: Cemdisiran, Pozelimab	Phase 3	Active, closed	2021-12	UK, USA, India, China
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) NCT02612454 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drug: Dupilumab	Phase 3	Active, closed	2015-10	UK, USA
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) NCT05394116 · ClinicalTrials.gov ↗ · Fibrodysplasia Ossificans Progressiva Drug: Garetosmab	Phase 3	Active, closed	2022-11	UK, USA, China
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy NCT05568459 · ClinicalTrials.gov ↗ · Hemophilia B	Observational	Active, closed	2024-01	UK, USA
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) NCT05557591 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer Drugs: BNT116, Cemiplimab	Phase 2	Active, closed	2023-04	USA
Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next) NCT04515524 · ClinicalTrials.gov ↗ · Retinopathy of Prematurity	Observational	Active, closed	2021-02	USA
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma NCT06097364 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL) Drugs: Cyclophosphamide, Doxorubicin, Odronextamab	Phase 3	Active, closed	2023-11	UK, USA
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy NCT06369467 · ClinicalTrials.gov ↗ · Food Allergy Drugs: Dupilumab, Linvoseltamab	Phase 1	Active, closed	2024-05	USA
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies NCT03888105 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma (B-NHL) Drug: Odronextamab	Phase 2	Active, closed	2019-11	UK, USA, China
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma NCT06190951 · ClinicalTrials.gov ↗ · Melanoma Drugs: Cemiplimab, Fianlimab	Phase 2	Active, closed	2024-09	USA
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US NCT07431086 · ClinicalTrials.gov ↗ · Overweight or Obesity Drug: Olatorepatide	Phase 2	Active, closed	2026-03	USA
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) NCT06465329 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Cemiplimab, Marlotamig	Phase 2	Active, closed	2024-11	USA
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma NCT06572228 · ClinicalTrials.gov ↗ · Asthma Drugs: Dupilumab, Ics-Laba	Phase 4	Active, closed	2024-08	USA
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation NCT06299098 · ClinicalTrials.gov ↗ · Obesity Drugs: Garetosmab, Semaglutide	Phase 2	Active, closed	2024-03	USA
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer NCT05800015 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Cemiplimab, Cisplatin	Phase 2/3	Active, closed	2023-08	USA
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants NCT06269133 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer Drug: Cemiplimab	Observational	Active, closed	2024-02	USA
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers NCT04626635 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: Bevacizumab, Cemiplimab, Marlotamig	Phase 1/2	Active, closed	2020-12	USA
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) NCT05785767 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer Drugs: Cemiplimab, Fianlimab	Phase 2/3	Active, closed	2023-06	USA
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients NCT03916627 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma Drugs: Cemiplimab, Fianlimab	Phase 2	Active, closed	2019-07	USA
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care NCT06693531 · ClinicalTrials.gov ↗ · Eosinophilic Esophagitis (EoE)	Observational	Active, closed	2024-11	USA
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) NCT06491914 · ClinicalTrials.gov ↗ · Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema Drug: Aflibercept	Phase 3	Active, closed	2024-07	USA
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) NCT04959448 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyposis Drug: Dupilumab	Observational	Active, closed	2021-08	USA
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have NCT05831176 · ClinicalTrials.gov ↗ · Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID) Drug: Dupilumab	Phase 2	Active, closed	2023-05	USA
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer NCT04077099 · ClinicalTrials.gov ↗ · NSCLC	Phase 1/2	Active, closed	2020-01	USA
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery NCT06161441 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer Drugs: Carboplatin, Cemiplimab, Cisplatin	Phase 2	Active, closed	2024-07	USA
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA) NCT05092347 · ClinicalTrials.gov ↗ · Chronic Kidney Disease (CKD) Drug: Vonsetamig	Phase 1/2	Active, closed	2022-08	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Regeneron Pharmaceuticals in the EU trials register (CTIS)

13 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Regeneron Pharmaceuticals as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
REGN9220 in Combination with Odronextamab in Adult Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) 2025-524780-20-00 · Hemic and Lymphatic Diseases	Phase 1	Authorised	Belgium
A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma 2025-523252-31-00 · Neoplasms Drugs: Daratumumab, Linvoseltamab	Phase 3	Authorised	Italy, Spain, Poland + 4 more
A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation 2025-524392-23-00 · Respiratory Tract Diseases Drug: Dupilumab	Phase 4	Authorised	Belgium, Italy, Spain
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis 2026-525844-14-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 1	Authorised	Belgium
Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation 2026-525464-18-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Belgium
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults 2025-523562-24-00 · CTIS ↗ · Not possible to specify	Phase 1	Authorised	Belgium
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies 2025-523399-22-00 · CTIS ↗ · Neoplasms Drugs: Cemiplimab, REGN10597	Phase 1	Authorised	Italy, Spain, Germany + 1 more
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I) 2024-519298-21-00 · CTIS ↗ · Hemic and Lymphatic Diseases Drug: Cenvacibart	Phase 3	Authorised	Belgium, Czechia, France + 5 more
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN) 2025-520479-25-00 · CTIS ↗ · Hemic and Lymphatic Diseases Drug: Cenvacibart	Phase 3	Authorised	Greece, Italy, Spain
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension 2024-514754-79-00 · CTIS ↗ · Cardiovascular Diseases	Phase 2	Ongoing	Latvia, Belgium, France + 4 more
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma 2024-519504-27-00 · CTIS ↗ · Neoplasms Drugs: Bortezomib, Carfilzomib, Daratumumab	Phase 3	Authorised	Greece, Spain, Poland + 7 more
An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene 2024-518674-14-00 · CTIS ↗ · Hormonal diseases	Phase 3	Authorised	Germany, Spain
A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria with Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy 2024-519709-37-00 · CTIS ↗ · Hemic and Lymphatic Diseases Drugs: Cemdisiran, Pozelimab	Phase 3	Authorised	Poland, Italy, Spain

Drugs in Regeneron Pharmaceuticals trials

60 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 20 more in the trial list above.

Conditions in Regeneron Pharmaceuticals trials

93 conditions

Melanoma6 Multiple Myeloma3 Atopic Dermatitis3 Atrial Fibrillation (AF)3 Overweight or Obesity3 Fallopian Tube Cancer3 Paroxysmal Nocturnal Hemoglobinuria2 Follicular Lymphoma (FL)2 Hemophilia B2Geographic Atrophy (GA)2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)2Advanced Non-Small Cell Lung Cancer2Venous Thromboembolism (VTE)2Advanced Solid Tumors2Eosinophilic Esophagitis (EoE)2Metastatic Castration-Resistant Prostate Cancer (mCRPC)2Clear Cell Renal Cell Carcinoma (ccRCC)2Non-small Cell Lung Cancer2 Ovarian Cancer2 Primary Peritoneal Cancer2Chronic Kidney Disease (CKD)2Diffuse Large B-cell Lymphoma (DLBCL)1Monoclonal Gammopathy of Undetermined Significance (MGUS)1Smoldering Multiple Myeloma (SMM)1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	89	56
Clinical trials in UK	29	18
Clinical trials in Ireland	6	2
Clinical trials in China	5	1
Clinical trials in India	4	1
EU register (CTIS)	13	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Melanoma

Sponsor	Trials
Iovance Biotherapeutics	2
Pierre Fabre Medicament	2
Shanghai Henlius Biotech	2
Binhui Biopharmaceutical	2
ImmVira Pharma	1
Rise Therapeutics	1
Zhuhai Yufan Biotechnologies	1
Suzhou BlueHorse Therapeutics	1
Hangzhou DAC Biotechnology	1

Sponsors with the most current trials registered for this condition.

Questions about Regeneron Pharmaceuticals trials

How many clinical trials does Regeneron Pharmaceuticals sponsor?

Regeneron Pharmaceuticals is the lead sponsor of 92 current trials on ClinicalTrials.gov in our USA, UK, Ireland, China and India registers, and 13 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Regeneron Pharmaceuticals trials recruiting?

Yes. 59 of its 92 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Regeneron Pharmaceuticals testing?

Its current trials name 60 drugs and biologicals as interventions. The most frequent are Cemiplimab (25), Linvoseltamab (13), Fianlimab (11), Cenvacibart (9) and Dupilumab (9). The number in brackets is how many of its trials name each drug.

Does Regeneron Pharmaceuticals have clinical trials in Ireland?

Yes. 6 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Regeneron Pharmaceuticals clinical trials